SENORES PHARMACEUTICALS LIMITED

BSE: SENORES544319ISIN INE0RB801010

Healthcare
Pharmaceuticals
BSE Healthcare

Share price

₹1,136.35-7.50 (-0.66%)

as of 4 Nov 2026

Prices adjusted for splits and bonuses; cash dividends excluded. Volume shows actual shares traded.

52W high: ₹1,599.55
52W low: ₹708.10
Off 52W high: -28.96%
1M return: -14.09%
3M return: -14.09%
6M return: +23.74%
1Y return: +48.19%
20D avg volume: 17,645
50 DMA: ₹1,355.60
200 DMA: ₹1,118.84

Key ratios Consolidated

Market cap: ₹5,233 Cr
Current price: ₹1,136.35
52W high / low: ₹1,599.55 / ₹708.10
Face value: ₹10.00
P/E: 38.12
P/B: 5.22
EPS (TTM): ₹29.81
Book value / share: ₹217.80
ROE: —
ROCE: 15.60%
Operating margin: —
Net margin: —
Debt / equity: 0.34
Net debt: ₹281.54 Cr
Interest cover: 7.36
Dividend yield: —
Dividend / share (TTM): —
Payout: —
Cash conversion cycle: 103.5 days

Financials

Metric	Q2 FY27	Q1 FY27	Q4 FY26	Q3 FY26	Q2 FY26	Q1 FY26	Q4 FY25	Q3 FY25	Q4 FY24
Income statement
	192.33	180.21	175.19	174.56	161.76	137.99	114.21	103.02	—
	8.94	2.81	17.67	3.78	5.41	3.36	11.77	5.16	—
	201.27	183.02	192.86	178.34	167.17	141.35	125.98	108.17	—
	153.69	143.56	145.46	133.74	126.53	114.86	105.30	87.69	—
	28.39	31.15	27.05	36.96	46.09	29.38	20.94	23.10	—
	37.45	34.01	35.71	37.87	11.00	27.55	29.06	22.13	—
	32.41	29.91	30.32	30.66	29.62	21.65	14.63	19.01	—
	8.77	7.17	8.46	5.33	6.19	5.04	5.30	6.16	—
	10.25	9.94	9.30	7.85	8.09	6.00	5.23	4.20	—
	35.68	30.82	31.16	22.88	25.55	20.81	22.68	17.63	—
	47.58	39.46	47.40	44.60	40.64	26.49	20.68	20.48	—
	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	—
	47.58	39.46	47.40	44.60	40.64	26.49	20.68	20.48	—
	10.98	9.01	10.73	11.02	10.52	5.31	2.71	4.05	—
	36.60	30.45	36.67	33.58	30.12	21.18	17.97	16.43	—
	8.85	6.61	7.96	7.29	6.54	4.60	3.81	5.04	—
Key metrics
	66.60	56.57	65.16	57.78	54.92	37.53	31.21	30.84	—
	34.60%	31.40%	37.20%	33.10%	34.00%	27.20%	27.30%	29.90%	—
	19.00%	16.90%	20.90%	19.20%	18.60%	15.30%	15.70%	15.90%	—
	4.40%	—	4.70%	—	4.60%	—	2.60%	—	—
	18.90%	30.60%	53.40%	69.40%	—	—	—	—	—
	21.50%	43.80%	104.10%	104.40%	—	—	—	—	—

Metric	TTM	FY26	FY25	FY24
Income statement
	722.29	632.63	398.25	—
	33.20	47.06	19.26	—
	755.49	679.69	417.51	—
	576.45	520.59	346.94	—
	123.55	114.27	91.64	—
	145.04	137.32	89.82	—
	123.30	112.25	60.37	—
	29.73	25.03	21.55	—
	37.34	31.25	16.84	—
	120.54	100.40	67.48	—
	179.04	159.10	70.57	—
	0.00	0.00	0.00	—
	179.04	159.10	70.57	—
	41.74	37.57	12.23	—
	137.30	121.53	58.34	—
	30.71	26.39	16.12	—
Key metrics
	246.11	215.38	108.96	—
	34.07%	34.00%	27.40%	—
	19.01%	19.20%	14.60%	—
	—	15.60%	9.30%	—
	39.71%	58.90%	—	—
	60.21%	108.30%	—	—
	—	-178.08	-203.44	—
	—	0.51	-0.79	—
	—	0.34	0.38	—
	—	281.54	199.38	—
	—	103.5	103.8	—
Balance sheet
	—	1,604	1,227	—
	—	812.43	722.43	—
	—	45.55	105.38	—
	—	324.82	123.88	—
	—	89.29	56.63	—
	—	66.03	39.45	—
	—	331.37	198.85	—
	—	234.72	67.22	—
	—	424.00	240.70	—
	—	327.09	304.76	—
	—	132.20	142.30	—
	—	194.89	162.46	—
	—	964.54	812.24	—
Cash flow
	—	62.05	-45.92	—
	—	-120.56	-429.48	—
	—	-1.32	573.14	—
	—	240.13	157.52	—

Metric	Q1 FY27	Q4 FY26	Q3 FY26	Q2 FY26	Q1 FY26	Q4 FY25	Q3 FY25	Q4 FY24
Income statement
	26.99	36.81	28.76	35.33	19.82	11.86	9.59	—
	9.55	22.19	9.78	11.36	8.39	9.25	7.19	—
	36.54	59.00	38.54	46.69	28.21	21.11	16.78	—
	35.15	46.31	35.02	39.04	24.62	18.21	15.46	—
	7.47	18.36	3.78	1.00	1.40	2.81	1.83	—
	4.19	5.10	11.98	11.00	2.34	7.46	2.40	—
	10.10	11.12	9.16	11.59	6.91	4.45	4.92	—
	2.22	1.89	1.75	1.58	1.76	2.35	2.70	—
	3.61	4.13	3.58	3.65	1.88	1.27	0.76	—
	7.07	5.65	8.16	10.59	6.92	3.41	1.78	—
	1.39	12.69	3.52	7.65	3.59	2.90	1.32	—
	0.00	0.00	0.00	0.00	0.00	0.00	—	—
	1.39	12.69	3.52	7.65	3.59	2.90	1.32	—
	0.36	4.21	0.87	1.22	0.89	0.88	0.25	—
	1.03	8.48	2.65	6.43	2.70	2.02	1.07	—
	0.22	1.84	1.98	1.40	0.59	0.39	0.32	—
Key metrics
	7.22	18.71	8.85	12.88	7.23	6.52	4.78	—
	26.80%	50.80%	30.80%	36.50%	36.50%	55.00%	49.80%	—
	3.80%	23.00%	9.20%	18.20%	13.60%	17.00%	11.20%	—
	—	1.80%	—	1.20%	—	0.70%	—	—
	36.20%	210.40%	199.90%	—	—	—	—	—
	-61.90%	319.80%	147.70%	—	—	—	—	—

Metric	TTM	FY26	FY25	FY24
Income statement
	127.89	106.09	38.54	—
	52.88	66.35	21.99	—
	180.77	172.44	60.53	—
	155.52	144.98	55.42	—
	30.61	24.55	7.26	—
	32.27	30.42	14.67	—
	41.97	38.78	18.25	—
	7.44	6.98	6.52	—
	14.97	13.23	3.08	—
	31.47	31.32	9.74	—
	25.25	27.46	5.11	—
	0.00	0.00	0.00	—
	25.25	27.46	5.11	—
	6.66	7.21	1.42	—
	18.59	20.25	3.69	—
	5.44	4.40	1.02	—
Key metrics
	47.66	47.67	14.71	—
	37.27%	44.90%	38.20%	—
	14.54%	19.10%	9.60%	—
	—	4.20%	1.50%	—
	—	175.30%	—	—
	—	448.80%	—	—
	—	-61.74	-69.52	—
	—	-1.33	-5.53	—
	—	0.10	0.13	—
	—	39.29	12.77	—
	—	188.5	201.2	—
Balance sheet
	—	887.91	834.09	—
	—	255.64	412.08	—
	—	32.22	81.20	—
	—	76.46	25.69	—
	—	9.75	8.66	—
	—	23.42	17.15	—
	—	97.92	46.23	—
	—	31.43	13.10	—
	—	69.56	41.23	—
	—	71.51	93.97	—
	—	19.74	17.71	—
	—	51.77	76.26	—
	—	749.90	707.96	—
Cash flow
	—	-26.88	-20.40	—
	—	-19.46	-162.93	—
	—	-2.64	532.62	—
	—	34.86	49.12	—

Compounded growth

Standalone

Sales CAGR 3Y: —
Sales CAGR 5Y: —
Profit CAGR 3Y: —
Profit CAGR 5Y: —
Sales YoY (TTM): —
Profit YoY (TTM): —

Consolidated

Sales CAGR 3Y: —
Sales CAGR 5Y: —
Profit CAGR 3Y: —
Profit CAGR 5Y: —
Sales YoY (TTM): +39.71%
Profit YoY (TTM): +60.21%

Compounded from reported annual figures. We publish no share-price CAGR: our prices are as-traded, so one would be wrong across every split and bonus issue.

Shareholding as of 30 Sep 2026

Promoter holding: 45.81%

Quarter	September 2026	June 2026	March 2026
Promoter %	45.81%	45.81%	45.81%

Holder	Type	Holding	Previous	Change
Swapnil Jatin Shah	Promoter	7.72%	7.72%	0.00%
Ashokbhai Vijaysinh Barot	Promoter	7.55%	7.48%	+0.07%
Remus Pharmaceuticals Limited	Promoter Group	7.08%	7.08%	0.00%
Renosen Pharmaceuticals Private Limited	Promoter Group	5.90%	5.90%	0.00%
Anar Swapnil Shah	Promoter Group	4.98%	4.98%	0.00%
Aviraj Overseas LLC	Promoter Group	4.12%	4.12%	0.00%
HSBC MUTUAL FUND - HSBC MULTI CAP FUND	Public	2.87%	—	—
Sangeeta Mukur Barot	Promoter Group	2.26%	2.26%	0.00%
MANOJ PRAKASH SANGHVI	Public	1.86%	1.86%	0.00%
RATNAMANI MARKETING PRIVATE LIMITED	Public	1.82%	1.82%	0.00%
BAJAJ FINSERV FLEXI CAP FUND	Public	1.79%	—	—
Aviraj Group LLC	Promoter Group	1.49%	1.49%	0.00%
ASTORNE CAPITAL VCC - ARVEN	Public	1.36%	1.95%	-0.59%
ADITYA BIRLA SUN LIFE INSURANCE COMPANY LIMITED	Public	1.28%	1.62%	-0.34%
TRUSTMF SMALL CAP FUND	Public	1.23%	—	—

Public shareholders are disclosed individually only above 1%.

Peer comparison

Company	Mkt cap (₹ Cr)	Price (₹)	P/E	ROCE	Sales YoY	Profit YoY	1Y return
Sun Pharmaceutical Industries Ltd.	4,26,112	1,776.00	38.78	17.90%	+12.13% TTM	+4.79% TTM	+4.92%
Divi's Laboratories Ltd.	2,66,424	10,036.00	91.09	19.00%	+16.35% TTM	+26.84% TTM	+47.61%
Torrent Pharmaceuticals Ltd.	1,79,908	4,730.00	85.71	9.10%	+42.06% TTM	-1.92% TTM	+32.24%
Laurus Labs Limited	1,24,601	2,306.10	93.53	19.70%	+23.03% TTM	+95.38% TTM	+134.59%
Zydus Lifesciences Limited	1,18,703	1,190.00	25.85	19.20%	+21.11% TTM	-2.51% TTM	+22.32%
Dr. Reddy's Laboratories Ltd.	1,14,513	1,372.00	41.50	13.90%	-3.53% TTM	-51.90% TTM	+14.26%
Cipla Ltd.	1,13,110	1,400.10	39.63	14.90%	-0.74% TTM	-47.48% TTM	-6.88%
Mankind Pharma Limited	1,04,631	2,533.15	46.22	13.70%	+13.27% TTM	+27.60% TTM	+6.91%
Aurobindo Pharma Ltd.	97,878	1,701.10	26.38	13.60%	+9.09% TTM	+9.48% TTM	+47.79%
Lupin Ltd	92,145	2,015.00	17.65	28.40%	+24.22% TTM	+20.10% TTM	+0.84%
Glenmark Pharmaceuticals ltd	70,608	2,501.85	39.27	16.20%	+32.94% TTM	+138.48% TTM	+35.48%
Alkem Laboratories Limited	62,054	5,190.00	28.15	18.80%	+13.36% TTM	-5.52% TTM	-8.38%
Abbott India Ltd. S	57,685	27,146.85	35.73	41.90%	+6.29% TTM	+11.18% TTM	-7.56%
Biocon Ltd.	56,061	344.00	134.63	2.90%	+5.70% TTM	-55.37% TTM	-9.53%
Gland Pharma Limited	52,105	3,157.70	46.16	13.70%	+17.57% TTM	+46.55% TTM	+65.09%
Ipca Laboratories Ltd.	50,051	1,973.15	36.40	16.40%	+10.59% TTM	+67.91% TTM	+52.33%
GlaxoSmithkline Pharmaceuticals Ltd.	42,904	2,532.60	37.42	55.40%	+12.12% TTM	+20.03% TTM	-4.84%
Ajanta Pharma Ltd.	41,406	3,313.55	32.79	29.40%	+25.01% TTM	+29.70% TTM	+26.89%
Emcure Pharmaceuticals Limited	41,254	2,174.55	37.75	25.10%	+21.12% TTM	+33.34% TTM	+64.07%
J.B. Chemicals & Pharmaceuticals Lt	38,731	2,412.25	47.77	21.90%	+5.87% TTM	+7.56% TTM	+45.79%
Sai Life Sciences Limited	32,855	1,546.30	90.80	18.10%	—	—	+67.49%
PIRAMAL PHARMA LIMITED	31,659	237.80	-151.21	0.80%	+9.43% TTM	-781.93% TTM	+18.60%
ACUTAAS CHEMICALS LIMITED	30,928	3,777.65	70.51	27.70%	+45.18% TTM	+95.78% TTM	+106.30%
Wockhardt Ltd	30,869	1,899.80	76.22	6.40%	+25.70% TTM	+894.12% TTM	+39.18%
RUBICON RESEARCH LIMITED	28,416	1,716.55	98.59	24.30%	—	—	+164.06%
SENORES PHARMACEUTICALS LIMITED	5,233	1,136.35	38.12	15.60%	+39.71% TTM	+60.21% TTM	+48.19%

Filings & corporate actions

Recent announcements

Senores Pharmaceuticals Limited has informed the exchange regarding Newspaper publication extracts of unaudited financial results for the quarter and half year ended September 30, 202630 Oct 2026 · Company Update / Newspaper Publication
Senores Pharmaceuticals Limited has informed the exchange regarding audio recording of earnings conference call for quarter ended September 30, 202629 Oct 2026 · Company Update / Analyst / Investor Meet
Senores Pharmaceuticals Limited has informed the exchange regarding submission of statement of deviation or variation in utilisation of funds raised through preferential issue of convertible ....29 Oct 2026 · Company Update / Reg. 32 (1), (3) - Statement of Deviation & Variation
Senores Pharmaceuticals Limited has informed the exchange regarding submission of statement of deviation or variation in utilisation of funds of public issue for quarter ended on September 30, 202629 Oct 2026 · Company Update / Reg. 32 (1), (3) - Statement of Deviation & Variation
Senores Pharmaceuticals Limited has informed the exchange regarding Monitoring Agency report for the quarter ended September 30, 202629 Oct 2026 · Company Update / Monitoring Agency Report
We enclose herewith the Investor Presentation for Q2 & H1FY2729 Oct 2026 · Company Update / Investor Presentation
Senores Pharmaceuticals Limited has informed the exchange regarding Appointment of joint Statutory Auditor of the Company29 Oct 2026 · Company Update / Appointment of Statutory Auditor/s
Senores Pharmaceuticals Limited has informed the exchange regarding media release29 Oct 2026 · Company Update / Press Release / Media Release
Senores Pharmaceuticals Limited has informed the exchange about subsidiary companies capacity expansion29 Oct 2026 · Company Update / General
Senores Pharmaceuticals Limited has informed the exchange regarding unaudited financial results for quarter ended September 30, 202629 Oct 2026 · Result / Financial Results
Outcome of Board Meeting held on October 29, 202629 Oct 2026 · Board Meeting / Outcome of Board Meeting
We hereby inform you that the timing of the earnings conference call to discuss the financial results for the second quarter of FY 2026-27 (Q2 FY27) has been re-scheduled to 04:00 P.M. ....23 Oct 2026 · Company Update / Analyst / Investor Meet
We hereby inform that, post announcement of Un-audited Consolidated and Standalone Financial Results for the quarter and half year ended on September 30, 2026, the Company will hold the ....22 Oct 2026 · Company Update / Analyst / Investor Meet
Senores Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 29/10/2026 ,inter alia, to consider and approve 1. The Un-audited ....22 Oct 2026 · Board Meeting / Board Meeting
Please find enclosed herewith copies of Newspaper publications regarding completion of dispatch of Notice of Postal Ballot, information of e-voting and other related information.17 Oct 2026 · Company Update / Newspaper Publication
Senores Pharmaceuticals Limited has informed the Exchange regarding Notice of Postal Ballot16 Oct 2026 · AGM/EGM / Postal Ballot
The Board at its meeting held today has re-appointed Mr. Swapnil Jatinbhai Shah as the Managing Director of the Company and Mr. Chetan Bipinchandra Shah as the Whole-time Director of the Company.13 Oct 2026 · Company Update / Change in Management
The Board of Directors of the Company at their Meeting held today i.e., Tuesday, October 13, 2026, has approved the following: 1. Re-Appointment of Mr. Swapnil Jatinbhai Shah (DIN: 05259821) ....13 Oct 2026 · Others / Outcome without intimation
Senores Pharmaceuticals Limited has informed the Exchange about the certificate under Regulation 74(5) of SEBI (Depositories and Participants) Regulation, 2018 for the quarter ended September 30, 20268 Oct 2026 · Company Update / Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
Senores Pharmaceuticals Limited has informed the Exchange regarding Scrutinizer Report and Voting results of 09th Annual General Meeting28 Sep 2026 · AGM/EGM / AGM
Proceedings of the 9th Annual General Meeting of the Company held on September 25, 202625 Sep 2026 · AGM/EGM / AGM
Intimation pertaining to closure of trading window24 Sep 2026 · Insider Trading / SAST / Closure of Trading Window
Clarification Letter on volume movement in the scrip of the Company21 Sep 2026 · Company Update / General
The Exchange has sought clarification from Senores Pharmaceuticals Ltd on September 21, 2026, with reference to Movement in Volume.<BR><BR>The reply is awaited.21 Sep 2026 · Company Update / Clarification
We are pleased to announce that the USFDA has successfully completed its inspection at the manufacturing facility of Apnar Pharma Private Limited11 Sep 2026 · Company Update / General
We are submitting herewith the Corrigendum to the Annual Report of the Company for the financial year 2025-26.9 Sep 2026 · Others / Reg. 34 (1) Annual Report
We are enclosing herewith the Newspaper Publication for the 9th Annual General Meeting of the Company.4 Sep 2026 · Company Update / Newspaper Publication
We are submitting herewith the copy of Business Responsibility and Sustainability Report of the Company for the financial year 2025-26.3 Sep 2026 · Others / Business Responsibility and Sustainability Reporting (BRSR)
We are submitting herewith the Annual Report of the Company for the financial year 2025-26.3 Sep 2026 · Others / Reg. 34 (1) Annual Report
We are submitting herewith the notice convening the 9th Annual general Meeting of the Company and Annual Report for the financial year 2025-263 Sep 2026 · AGM/EGM / AGM
Senores Pharmaceuticals Limited has informed the Exchange regarding Analyst/ Institutional Investor Meet scheduled to be held on September 02, 202627 Aug 2026 · Company Update / Analyst / Investor Meet
Senores Pharmaceuticals Limited has informed the Exchange regarding copy of newspaper publication for pre dispatch of Annual Report for the forthcoming Annual General Meeting of the Company27 Aug 2026 · Company Update / Newspaper Publication
Senores Pharmaceuticals Limited has informed the Exchange regarding Appointment of Independent Director26 Aug 2026 · Company Update / Change in Management
Senores Pharmaceuticals Limited has informed the Exchange regarding appointment of Company Secretary and Compliance Officer of the Company26 Aug 2026 · Company Update / Appointment of Company Secretary / Compliance Officer
Senores Pharmaceuticals Limited has informed the Exchange regarding proposed incorporation of Subsidiary Company in Canada26 Aug 2026 · Company Update / Acquisition
Senores Pharmaceuticals Limited has informed the Exchange regarding proposed incorporation of Wholly owned subsidiary in Mexico26 Aug 2026 · Company Update / Acquisition
Senores Pharmaceuticals Limited has informed the Exchange about Outcome of Board Meeting held on August 26, 202626 Aug 2026 · Others / Outcome without intimation
Senores Pharmaceuticals Limited has informed the Exchange regarding giving corporate guarantee for credit facilities availed by Apnar Pharma Private Limited, Subsidiary of the Company from ....24 Aug 2026 · Company Update / General
Senores Pharmaceuticals Limited has informed the Exchange regarding Analyst/ Institutional Investor Meet scheduled to be held on August 25, 202620 Aug 2026 · Company Update / Analyst / Investor Meet
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Dhananjay Barot12 Aug 2026 · Insider Trading / SAST / Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011

Board meetings

29 Oct 2026 Board Meeting - Financial Results
27 Jul 2026 Board Meeting - Financial Results